27 July 2021 - LYN-014 has the potential to address significant public health concerns about access to opioid use disorder treatment and reduce patients’ need for daily methadone administration.
Lyndra Therapeutics today announced that LYN-014, the company’s oral, ultra long-acting, extended release levomethadone capsule in development for the weekly treatment of opioid use disorder, has received fast track designation from the U.S. FDA.